The following table presents unaudited quarterly consolidated operating results for each of the Company’s last eight fiscal quarters. This information below has been prepared on a basis consistent with the Company’s audited consolidated financial statements.



(in millions, except per share amounts)
Fiscal 2014	First Quarter⁽²⁾		Second Quarter⁽³⁾			Third Quarter⁽⁴⁾		Fourth Quarter⁽⁵⁾
Net sales	$	933.4	$	979.0		$	1,004.2	$	1,144.2
Gross profit	$	356.3	$	360.7		$	315.0	$	415.7
Net income (loss)	$	111.4	$	(86.0	)	$	48.1	$	131.7
Earnings (loss) per share⁽¹⁾:
Basic	$	1.18	$	(0.87	)	$	0.36	$	0.98
Diluted	$	1.18	$	(0.87	)	$	0.36	$	0.98
Weighted average shares outstanding
Basic	94.2		98.7			133.7		133.8
Diluted	94.7		98.7			134.3		134.3



(in millions, except per share amounts)
Fiscal 2013	First Quarter⁽⁶⁾		Second Quarter⁽⁷⁾		Third Quarter⁽⁸⁾		Fourth Quarter⁽⁹⁾
Net sales ⁽¹⁾	$	769.8	$	883.0	$	919.8	$	967.2
Gross profit ⁽¹⁾	$	285.3	$	307.2	$	331.4	$	356.2
Net income	$	105.6	$	106.0	$	111.9	$	118.5
Earnings per share⁽¹⁾:
Basic	$	1.13	$	1.13	$	1.19	$	1.26
Diluted	$	1.12	$	1.12	$	1.18	$	1.25
Weighted average shares outstanding
Basic	93.6		93.9		94.0		94.0
Diluted	94.3		94.5		94.5		94.6


(1)	The sum of quarterly financial data may vary from the annual data due to rounding. The sum of individual per share amounts may not equal due to rounding.


(2)	Includes Elan transaction costs of $12.0 million, litigation settlement of $2.5 million, and acquisition costs of $1.9 million.


(3)	Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, restructuring charges totaling $14.9 million, write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D of $6.0 million related to Paddock and Rosemont.


(4)	Includes restructuring charges totaling $19.5 million, write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs.


(5)	Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.


(6)	Includes a pre-tax charge of approximately $1.9 million of acquisition costs associated with the Sergeant's acquisition.


(7)	Includes a pre-tax charge to cost of sales of $7.7 million associated with the step-up in value of inventory related to the Sergeant's acquisition, $1.5 million of severance costs associated with the Cobrek acquisition and a $3.0 million loss on the sale of investment related to Cobrek.


(8)	Includes a pre-tax charge to cost of sales of $1.9 million associated with the step-up in value of inventory related to the Rosemont acquisition, approximately $3.1 million of acquisition costs associated with the Rosemont and Velcera acquisitions and a $1.6 million loss related to the sale of the Company's investment securities.


(9)	Includes a pre-tax charge to cost of sales of $1.2 million associated with the step-up in value of inventory related to the Rosemont acquisition, $5.6 million of restructuring and other integration-related costs associated with the Velcera acquisition and a $9.0 million impairment charge related to the write-off of IPR&D.